Summit Therapeutics PLC (NASDAQ:SMMT – Get Free Report) saw unusually large options trading on Monday. Investors purchased 49,767 call options on the company. This represents an increase of approximately 424% compared to the average volume of 9,504 call options.
More Summit Therapeutics News
Investors following SMMT have been watching these news items:
- Neutral Sentiment: Barclays cut its price target to $18 from $20 and maintained an “equal weight” rating. The lower target reflects a more cautious outlook, although it remains above the price cited in the report. Barclays recommendations
- Negative Sentiment: The FDA issued a Complete Response Letter for Summit’s application seeking approval of ivonescimab with platinum-containing chemotherapy for certain patients with advanced or metastatic non-small cell lung cancer whose disease progressed after EGFR-targeted therapy. The application was not approved, delaying the drug’s potential commercialization; the company’s update did not specify the FDA’s concerns in the information provided. Summit Therapeutics’ ivonescimab application update
Hedge Funds Weigh In On Summit Therapeutics
A number of large investors have recently made changes to their positions in the company. Bank of New York Mellon Corp acquired a new stake in Summit Therapeutics during the second quarter worth about $6,284,000. BlackRock Inc. acquired a new position in shares of Summit Therapeutics in the 2nd quarter valued at approximately $138,838,000. Public Employees Retirement System of Ohio bought a new stake in shares of Summit Therapeutics during the 2nd quarter worth approximately $561,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Summit Therapeutics during the 2nd quarter worth approximately $4,342,000. Finally, Bank of America Corp DE acquired a new stake in shares of Summit Therapeutics during the 2nd quarter worth approximately $12,603,000. Institutional investors own 4.61% of the company’s stock.
Summit Therapeutics Trading Down 14.5%
SMMT stock traded down $2.06 during mid-day trading on Monday, hitting $12.09. 14,150,151 shares of the company were exchanged, compared to its average volume of 4,689,564. Summit Therapeutics has a 1-year low of $11.87 and a 1-year high of $29.23. The stock has a market capitalization of $9.67 billion, a PE ratio of -11.25 and a beta of -1.49. The business has a 50 day simple moving average of $16.41 and a 200-day simple moving average of $16.14.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on SMMT. Leerink Partners upgraded shares of Summit Therapeutics from an “underperform” rating to a “market perform” rating and boosted their price objective for the stock from $12.00 to $13.00 in a research note on Wednesday, August 12th. The Goldman Sachs Group set a $41.00 price target on Summit Therapeutics and gave the stock a “buy” rating in a report on Tuesday, September 29th. Cantor Fitzgerald reissued an “overweight” rating on shares of Summit Therapeutics in a research report on Tuesday, September 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Summit Therapeutics in a research report on Thursday, October 15th. Finally, Guggenheim reiterated a “buy” rating on shares of Summit Therapeutics in a research note on Wednesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $28.45.
View Our Latest Stock Analysis on Summit Therapeutics
About Summit Therapeutics
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer. Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit’s licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.
See Also
- Five stocks we like better than Summit Therapeutics
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
